A Stanford-led team has found two antibodies that can work together to defeat all SARS-CoV-2 variants. More research is needed, but the approach could help in the development of treatments to keep pace with evolving viruses.
How a Trump presidency could affect the FDA, the biotech industry, and its stocks
Is less regulation by the Food and Drug Administration good for the biotech industry? Do vaccine makers like Pfizer have a target on their back